Genotoxicity associated with the use of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Genotoxicity associated with the use of tyrosine kinase inhibitors in patients with chronic... Dear Editor,Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease in which proliferation of massive cells from the myeloid lineage occurs. The Philadelphia (Ph) chromosome is a CML genetic abnormality characteristic, and results from a reciprocal translocation between the long arms of chromosomes 9 and 22, generating a BCR‐ABL oncoprotein with constitutively activated tyrosine kinase activity [Druker et al., ].The development of tyrosine kinase inhibitors (TKIs) has revolutionized CML treatment because they are able to block cell proliferation of malignant clones by interfering with the interaction between a BCR‐ABL1 oncoprotein and adenosine triphosphate (ATP) [Jabbour and Kantarjian, ].Despite the success of TKIs for CML treatment, these drugs need to be monitored because of the occurrence of adverse events. Reports in the literature have described special situations with regard to TKI treatment safety. Some authors have reported the occurrence of cytogenetic changes in Ph– cells during treatment with imatinib and the presence of secondary disease that resembled myelodysplastic syndrome or acute myeloid leukemia has been observed in some patients [Medina et al., ; Loriaux and Deininger, ; Jabbour et al., ]. In another study, it was observed that stem cells from normal donors acquired post‐transplant cytogenetic changes during therapy with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Environmental and Molecular Mutagenesis Wiley

Loading next page...
 
/lp/wiley/genotoxicity-associated-with-the-use-of-tyrosine-kinase-inhibitors-in-c0bpeabGzp
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0893-6692
eISSN
1098-2280
D.O.I.
10.1002/em.22164
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease in which proliferation of massive cells from the myeloid lineage occurs. The Philadelphia (Ph) chromosome is a CML genetic abnormality characteristic, and results from a reciprocal translocation between the long arms of chromosomes 9 and 22, generating a BCR‐ABL oncoprotein with constitutively activated tyrosine kinase activity [Druker et al., ].The development of tyrosine kinase inhibitors (TKIs) has revolutionized CML treatment because they are able to block cell proliferation of malignant clones by interfering with the interaction between a BCR‐ABL1 oncoprotein and adenosine triphosphate (ATP) [Jabbour and Kantarjian, ].Despite the success of TKIs for CML treatment, these drugs need to be monitored because of the occurrence of adverse events. Reports in the literature have described special situations with regard to TKI treatment safety. Some authors have reported the occurrence of cytogenetic changes in Ph– cells during treatment with imatinib and the presence of secondary disease that resembled myelodysplastic syndrome or acute myeloid leukemia has been observed in some patients [Medina et al., ; Loriaux and Deininger, ; Jabbour et al., ]. In another study, it was observed that stem cells from normal donors acquired post‐transplant cytogenetic changes during therapy with

Journal

Environmental and Molecular MutagenesisWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial